BioAge to Present Phase 1 Data for NLRP3 Inhibitor BGE-102 in Cardiovascular and Retinal Diseases
Event summary
- BioAge Labs to host R&D Day on May 8, 2026, focusing on NLRP3 inhibition with BGE-102.
- Phase 1 clinical data for BGE-102 to be presented, targeting atherosclerotic cardiovascular disease (ASCVD) and retinal disease.
- Four academic and clinical experts to join BioAge management for presentations and Q&A.
- Phase 2 cardiovascular risk proof-of-concept data anticipated in H2 2026, Phase 1b/2a diabetic macular edema data in mid-2027.
The big picture
BioAge's focus on NLRP3 inhibition aligns with growing interest in targeting inflammation for cardiometabolic and retinal diseases. The company's proprietary discovery platform, built on human longevity data, positions it uniquely in the aging biology space. Success with BGE-102 could validate BioAge's approach and attract partnerships or investment, particularly as Phase 2 data nears.
What we're watching
- Clinical Validation
- Whether Phase 1 data for BGE-102 will demonstrate sufficient efficacy and safety to support advancement into Phase 2 trials.
- Market Differentiation
- How BGE-102's potential best-in-class attributes will position it against existing and emerging NLRP3 inhibitors.
- Indication Expansion
- The pace at which BioAge can expand BGE-102 into additional inflammatory diseases beyond ASCVD and retinal disease.
Related topics